Etanercept in the treatment of plaque psoriasis

Etanercept in childhood psoriasis: An experience from Kuwait

The Gulf Journal of Dermatology and Venereology ABSTRACT Psoriasis commonly affects children and adolescents, and the need for safe, effective therapy is a special consideration in the pediatric population. Recently, the use of biologic agents has been extensively studied for the treatment of psoriasis in adults. Of these, etanercept, a tumor necrosis factor-α antagonist, which FDA has approved...

The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.

Many patients with moderate-to-severe plaque psoriasis do not respond adequately to methotrexate monotherapy. This pilot study, with a small patient population, was performed to evaluate the effectiveness and safety of etanercept and methotrexate combination in patients with plaque psoriasis and inadequate response to methotrexate. Outpatients with plaque psoriasis (Psoriasis Area and Severity ...

DRUG EVALUATION Etanercept: a soluble TNF-α receptor in the treatment of psoriasis

10.2217/14750708.4.5.665 © 2 Among tumor necrosis factor (TNF)-α neutralizing drugs, etanercept is unique in as much as it is a recombinant, fully human, soluble form of the TNF-α receptor. Previously licensed for the treatment of adult and juvenile rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, recent double-blind, placebo-controlled, randomized trials have provided larg...

[Episode of pustular psoriasis after a tuberculin test in a patient with plaque psoriasis on treatment with etanercept].

A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate to-severe chronic plaque-type psoriasis: the Psoriasis Infiximab vs. Etanercept Comparison Evaluation (PIECE) study

There are no direct comparison data between infliximab and entanercept in the treatment of psoriasis. This study was a mult icenter, randomised control trial done in the Netherlands to compare the efficacy, outcome of etanercept vs. infliximab in the management of moderate to severe chronic plaque psoriasis. Patients (age 1875 years old) with Psoriasis Area and Severity Index (PASI) ≥10 and/or ...